New York Pharma Forum: Healthcare Policy’s Effect on Drug Innovation and Value: What’s at Stake for the Pharmaceutical and Biotech Industry

On Thursday afternoon, May 31st, New York Pharma Forum is holding a program in New York City on "Healthcare Policy's Effect on Drug Innovation and Value: What's at Stake for the Pharmaceutical and Biotech Industry." It is open to industry professionals (non-members as well as members), and is $130 to attend for non-members. New York Pharma Forum is a non-profit membership association that provides U.S. and Japanese biopharma executives a unique platform for networking and learning together with others who have an important impact on the global healthcare industry.

Debates surrounding U.S. healthcare policy continue to occupy center stage nationally. The stakeholders are anxiously awaiting the outcome of the Supreme Court's decision to the challenges to the constitutionality of the 2010 healthcare reform law (the Affordable Care Act). That, along with other possible changes in the healthcare environment, will definitely impact the biopharmaceutical community. Healthcare policy affects the threshold for pharmaceutical innovation that payers are willing to cover, which in turn can have a big effect on product portfolio development and licensing priorities. If the policy goal is to reward generics at the expense of innovative products, where is the value in R&D? In an environment where innovation is no longer valued, what are the value drivers?

This program will feature a discussion by industry executives from both policy and licensing sides of the industry on some of the issues surrounding changes in healthcare policy - issues that are not always addressed by policy makers. The speakers will examine the current healthcare policy landscape and its affect on the licensing of innovative therapies.

SPEAKERS:

Raul Damas

Senior Director, US Policy, Pfizer Inc.

Allen Downs

Senior Executive Director, Licensing & Business Development, Purdue Pharma L.P.

Michael McCaughan

Founding member, Prevision Policy LLC and Editor, The RPM Report

Catherine Sazdanoff

Vice President, Business Development, Takeda Pharmaceuticals International

Ira Weisberg

President, Weisberg Consulting LLC and Acting CEO and Director, AlphaVax

PLACE: The Nippon Club (212) 581-2223

145 West 57th St., (bet. 6th & 7th Aves.), New York City

TIME: Program: 3:30 - 5:30 pm in the Rose Room (2nd fl.)

Reception: 5:30 - 7:00pm in the Rose Room (2nd fl.)

To Register

QUESTIONS: Email Alexandra Huebner, ahuebner@bridgeny.com

Or call 212-583-1043 X14